Ocugen, Inc. (BMV:OCGN)

Market Cap	7.93B +109.3%
Revenue (ttm)	80.49M -1.3%
Net Income	-1.29B
EPS	-4.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46
Average Volume	337
Open	23.70
Previous Close	22.66
Day's Range	23.70 - 23.70
52-Week Range	16.00 - 45.50
Beta	n/a
RSI	38.65
Earnings Date	May 5, 2026

About Ocugen

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 116
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OCGN

Financial Performance

In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.

Financial numbers in USD